REG - ReNeuron Group plc - Grant of Options
15/02/2023 07:16
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230215:nRSO9328Pa&default-theme=true
RNS Number : 9328P ReNeuron Group plc 15 February 2023
ReNeuron Group plc
("ReNeuron" or "the Company" or "the Group")
Grant of Options
ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome
technologies, announces that grants were made on 14 February 2023 for options
over 4,030,000 Ordinary Shares of 1p each ("Options") under the terms of the
Company's Long Term Incentive Plan ("The Plan") and its Non-Executive Share
Option Scheme. The grants of 3,000,000 Options made to Directors and Persons
Discharging Managerial Responsibilities (PDMRs) are set out further in the
table below.
1,615,000 of the Options granted under The Plan have an exercise price of
10.25 pence per share, this being the closing mid-market price of the
Company's shares on 14 February 2023. The Options vest in equal proportions at
12, 24 and 36 months from the date of grant. These Options will be exercisable
if the share price of the Company's shares exceeds 31.5p for any single period
of at least 30 consecutive days.
The remaining 1,415,000 of the Options granted under The Plan have an exercise
price of 31.5 pence per share. The Options vest in equal proportions at 12, 24
and 36 months from the date of grant. None of these Options are subject to any
further performance conditions.
The 1,000,000 Options granted to Iain Ross are granted under the Non-Executive
Share Option Scheme. 750,000 of the Options are granted with an exercise
price of 10.25 pence per share, this being the closing mid-market price of the
Company's shares on 14 February 2023. These Options will be exercisable if the
share price of the Company's shares exceeds 31.5p for any single period of at
least 30 consecutive days. 250,000 of the Options are granted with an exercise
price of 50.0 pence per share without any further performance conditions. All
of Mr Ross's options vest monthly over three years on a straight-line basis.
Name Title Date of grant of Options Number of Options granted Total shares over which options are held (post award) Percentage of issued shares under option
Iain Ross Executive Chairman 14 February 2023 1,000,000 1,500,000 2.62%
John Hawkins Chief Financial Officer 14 February 2023 500,000 840,000 1.47%
Randolph Corteling Chief Scientific Officer 14 February 2023 500,000 1,000,000 1.75%
Simon Dew Chief Business Officer 14 February 2023 600,000 600,000 1.05%
Suzanne Hancock Chief Operations Officer 14 February 2023 400,000 749,326 1.31%
ENDS
Enquiries:
ReNeuron www.reneuron.com/investors (http://www.reneuron.com/investors)
Iain Ross, Chairman Via Walbrook PR
John Hawkins, Chief Financial Officer
Liberum Capital Limited (NOMAD and Joint Broker) +44 (0)20 3100 2000
Phil Walker (Investment Banking)
Richard Lindley (Investment Banking)
Ben Cryer (Investment Banking)
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
(mailto:reneuron@walbrookpr.com)
Paul McManus / Alice Woodings +44 (0)7980 541 893 / +44 (0)7407 804 654
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug
delivery platform with customisable cellular targeting capabilities for the
delivery of complex drug modalities.
Through the generation of several unique and scalable exosome producer cell
lines, our CustomEX™ platform can be optimised for specific tissues targets
and payloads leading to improvements in therapeutic outcome and a reduction in
off-target effects. ReNeuron offers a delivery mechanism for a variety of
payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC) platform, the
Company can make allogeneic tissue cells of choice and has the potential to
produce exosomes with tissue specific targeting ability.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com)
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
(Disclosure in relation to grant of share options to Directors and PDMRs)
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Iain Ross
2 Reason for the notification
a) Position/status Executive Chairman
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name ReNeuron Group plc
b) LEI 2138003TU12CQ5TZO137
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares 1p
Identification code RENE - GB00BF5G6K95
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) Price(s) Volume(s)
0.00 1,000,000
d) Aggregated information N/A
e) Date of the transaction 14 February 2023
f) Place of the transaction Outside of a trading venue
d)
Aggregated information
N/A
e)
Date of the transaction
14 February 2023
f)
Place of the transaction
Outside of a trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name John Hawkins
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name ReNeuron Group plc
b) LEI 2138003TU12CQ5TZO137
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares 1p
Identification code RENE - GB00BF5G6K95
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) Price(s) Volume(s)
0.00 500,000
d) Aggregated information N/A
e) Date of the transaction 14 February 2023
f) Place of the transaction Outside of a trading venue
d)
Aggregated information
N/A
e)
Date of the transaction
14 February 2023
f)
Place of the transaction
Outside of a trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Randolph Corteling
2 Reason for the notification
a) Position/status Chief Scientific Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name ReNeuron Group plc
b) LEI 2138003TU12CQ5TZO137
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares 1p
Identification code RENE - GB00BF5G6K95
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) Price(s) Volume(s)
0.00 500,000
d) Aggregated information N/A
e) Date of the transaction 14 February 2023
f) Place of the transaction Outside of a trading venue
d)
Aggregated information
N/A
e)
Date of the transaction
14 February 2023
f)
Place of the transaction
Outside of a trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Simon Dew
2 Reason for the notification
a) Position/status Chief Business Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name ReNeuron Group plc
b) LEI 2138003TU12CQ5TZO137
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares 1p
Identification code RENE - GB00BF5G6K95
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) Price(s) Volume(s)
0.00 600,000
d) Aggregated information N/A
e) Date of the transaction 14 February 2023
f) Place of the transaction Outside of a trading venue
d)
Aggregated information
N/A
e)
Date of the transaction
14 February 2023
f)
Place of the transaction
Outside of a trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Suzanne Hancock
2 Reason for the notification
a) Position/status Head of Operations
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name ReNeuron Group plc
b) LEI 2138003TU12CQ5TZO137
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares 1p
Identification code RENE - GB00BF5G6K95
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) Price(s) Volume(s)
0.00 400,000
d) Aggregated information N/A
e) Date of the transaction 14 February 2023
f) Place of the transaction Outside of a trading venue
d)
Aggregated information
N/A
e)
Date of the transaction
14 February 2023
f)
Place of the transaction
Outside of a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHKZLFFXLLZBBDRecent news on ReNeuron
See all newsREG - ReNeuron Group plc - Directorate Change
AnnouncementREG - FTSE Russell - ReNeuron Group
AnnouncementREG - ReNeuron Group plc - Appointment of Administrators
AnnouncementREG - ReNeuron Group plc - Intention to Appoint Administrators
AnnouncementREG - ReNeuron Group plc - Block Listing Review & Total Voting Rights
Announcement